Access to lower prescription drugs is critical to America’s patients. Biosimilar and generic drugs play a critical role and creating this access, saving patients and the public hundreds of billions of dollars annually, and almost two trillion dollars over the last decade. Both offer promise of lower costs and competitive treatment options for patients.
Did You Know?
- The 12 years of market exclusivity granted by the U.S. to brand biologic developers is the longest monopoly period of any country in the world
- The average copay for a generic drug is just $6.06
- 9 out of 10 prescriptions filled in the U.S. are generic medicines
- Atorvastatin, the generic version of Lipitor, saved Medicare more than $20 billion in one year alone
Unfortunately, market obstacles, such as anti-competitive tactics, misguided government policies and rampant misinformation campaigns, risk patient access to lifesaving biosimilars and generics.
Now in its tenth edition, this year’s “Generic Drug Access & Savings in the U.S.” report released by AAM shares insight into the impact of biosimilars and generics to date and provides a critical look at how brands’ anti-competitive practices can negatively impact patients.